Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study.
AIMS
the objectives of this study are to reveal the potential side effects after taking the covid19 vaccines, associated risk factors with severe side effects, and to compare the three COVID-19 vaccines available in Iraq (Sinopharm, AstraZeneca-Oxford and Pfizer- BioNTech).


METHODS
a randomized cross-sectional study was conducted in April 2021. A standardized questionnaire platform was utilized to collect information about the Iraqi population.


RESULTS
1012 were enrolled in the study, 60.2% were male and 39.8% were female. 84% were symptomatic post vaccination. Young aged participants, females, participants with history of COVID19 infection, those with comorbid diseases and AstraZeneca vaccine receivers were statistically significant risk factors for having adverse reactions post vaccination, P value (0.03, 0.028, 0.007, 0.019 and 0.0001) respectively. Regarding severity of symptoms, most symptoms were mild and moderate. Residency in Kurdistan Region of Iraq and AstraZeneca vaccine were the statistically significant risk factors for getting severe symptoms P value < 0.0001 of both. Females were an associated risk factor for D-dimer elevation P value = 0.05.


CONCLUSION
fatigue, injection site reactions, fever, myalgia, headache and chills were the most reported side effects. Most symptoms were mild to moderate in term of severity.
['Almufty|Hind B|HB|', 'Mohammed|Shinah A|SA|', 'Abdullah|Arshad M|AM|', 'Merza|Muayad A|MA|']
D000293:Adolescent D000328:Adult D000368:Aged D000369:Aged, 80 and over D000086382:COVID-19 D000086663:COVID-19 Vaccines D003430:Cross-Sectional Studies D005260:Female D006801:Humans D007493:Iraq D008297:Male D008875:Middle Aged D012189:Retrospective Studies D000086402:SARS-CoV-2 D014611:Vaccination D055815:Young Adult
Adverse effects COVID19 vaccine Sinopharm AstraZeneca-Oxford Pfizer- BioNTech